Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

Aziz Nazha, Hagop Kantarjian, Preetesh Jain, Carlos Romo, Elias Jabbour, Alfonso Quintas-Cardama, Raja Luthra, Lynne Abruzzo, Gautam Borthakur, Farhad Ravandi, Sherry Pierce, Susan O'Brien, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

Response to tyrosine kinase inhibitors at three months is a predictor for long-term outcome in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. We analyzed 456 newly diagnosed chronic myeloid leukemia patients treated with tyrosine kinase inhibitors to determine their outcome based on their response at six months. Forty-four (10%) patients did not achieve major cytogenetic response at three months: 18 of 67 (27%) patients treated with imatinib 400; 18 of 196 (9%) with imatinib 800; and 8 of 193 (4%) with 2nd generation tyrosine kinase inhibitors. Among them, 19 (43%) achieved major cytogenetic response at six months and subsequently had an overall outcome similar to the patients who achieved a major cytogenetic response at three months. In conclusion, the response to tyrosine kinase inhibitors at three months is a static, one-time measure. Assessing the response at six months of patients with poor response at three months may provide a better predictor for longterm outcome.

Original languageEnglish (US)
Pages (from-to)1686-1688
Number of pages3
JournalHaematologica
Volume98
Issue number11
DOIs
StatePublished - Nov 1 2013
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Protein-Tyrosine Kinases

ASJC Scopus subject areas

  • Hematology

Cite this

Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. / Nazha, Aziz; Kantarjian, Hagop; Jain, Preetesh; Romo, Carlos; Jabbour, Elias; Quintas-Cardama, Alfonso; Luthra, Raja; Abruzzo, Lynne; Borthakur, Gautam; Ravandi, Farhad; Pierce, Sherry; O'Brien, Susan; Cortes, Jorge.

In: Haematologica, Vol. 98, No. 11, 01.11.2013, p. 1686-1688.

Research output: Contribution to journalArticle

Nazha, A, Kantarjian, H, Jain, P, Romo, C, Jabbour, E, Quintas-Cardama, A, Luthra, R, Abruzzo, L, Borthakur, G, Ravandi, F, Pierce, S, O'Brien, S & Cortes, J 2013, 'Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months', Haematologica, vol. 98, no. 11, pp. 1686-1688. https://doi.org/10.3324/haematol.2013.090282
Nazha, Aziz ; Kantarjian, Hagop ; Jain, Preetesh ; Romo, Carlos ; Jabbour, Elias ; Quintas-Cardama, Alfonso ; Luthra, Raja ; Abruzzo, Lynne ; Borthakur, Gautam ; Ravandi, Farhad ; Pierce, Sherry ; O'Brien, Susan ; Cortes, Jorge. / Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. In: Haematologica. 2013 ; Vol. 98, No. 11. pp. 1686-1688.
@article{59f861c6b65145aeb2499ca5653c4219,
title = "Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months",
abstract = "Response to tyrosine kinase inhibitors at three months is a predictor for long-term outcome in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. We analyzed 456 newly diagnosed chronic myeloid leukemia patients treated with tyrosine kinase inhibitors to determine their outcome based on their response at six months. Forty-four (10{\%}) patients did not achieve major cytogenetic response at three months: 18 of 67 (27{\%}) patients treated with imatinib 400; 18 of 196 (9{\%}) with imatinib 800; and 8 of 193 (4{\%}) with 2nd generation tyrosine kinase inhibitors. Among them, 19 (43{\%}) achieved major cytogenetic response at six months and subsequently had an overall outcome similar to the patients who achieved a major cytogenetic response at three months. In conclusion, the response to tyrosine kinase inhibitors at three months is a static, one-time measure. Assessing the response at six months of patients with poor response at three months may provide a better predictor for longterm outcome.",
author = "Aziz Nazha and Hagop Kantarjian and Preetesh Jain and Carlos Romo and Elias Jabbour and Alfonso Quintas-Cardama and Raja Luthra and Lynne Abruzzo and Gautam Borthakur and Farhad Ravandi and Sherry Pierce and Susan O'Brien and Jorge Cortes",
year = "2013",
month = "11",
day = "1",
doi = "10.3324/haematol.2013.090282",
language = "English (US)",
volume = "98",
pages = "1686--1688",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "11",

}

TY - JOUR

T1 - Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

AU - Nazha, Aziz

AU - Kantarjian, Hagop

AU - Jain, Preetesh

AU - Romo, Carlos

AU - Jabbour, Elias

AU - Quintas-Cardama, Alfonso

AU - Luthra, Raja

AU - Abruzzo, Lynne

AU - Borthakur, Gautam

AU - Ravandi, Farhad

AU - Pierce, Sherry

AU - O'Brien, Susan

AU - Cortes, Jorge

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Response to tyrosine kinase inhibitors at three months is a predictor for long-term outcome in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. We analyzed 456 newly diagnosed chronic myeloid leukemia patients treated with tyrosine kinase inhibitors to determine their outcome based on their response at six months. Forty-four (10%) patients did not achieve major cytogenetic response at three months: 18 of 67 (27%) patients treated with imatinib 400; 18 of 196 (9%) with imatinib 800; and 8 of 193 (4%) with 2nd generation tyrosine kinase inhibitors. Among them, 19 (43%) achieved major cytogenetic response at six months and subsequently had an overall outcome similar to the patients who achieved a major cytogenetic response at three months. In conclusion, the response to tyrosine kinase inhibitors at three months is a static, one-time measure. Assessing the response at six months of patients with poor response at three months may provide a better predictor for longterm outcome.

AB - Response to tyrosine kinase inhibitors at three months is a predictor for long-term outcome in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. We analyzed 456 newly diagnosed chronic myeloid leukemia patients treated with tyrosine kinase inhibitors to determine their outcome based on their response at six months. Forty-four (10%) patients did not achieve major cytogenetic response at three months: 18 of 67 (27%) patients treated with imatinib 400; 18 of 196 (9%) with imatinib 800; and 8 of 193 (4%) with 2nd generation tyrosine kinase inhibitors. Among them, 19 (43%) achieved major cytogenetic response at six months and subsequently had an overall outcome similar to the patients who achieved a major cytogenetic response at three months. In conclusion, the response to tyrosine kinase inhibitors at three months is a static, one-time measure. Assessing the response at six months of patients with poor response at three months may provide a better predictor for longterm outcome.

UR - http://www.scopus.com/inward/record.url?scp=84886997780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886997780&partnerID=8YFLogxK

U2 - 10.3324/haematol.2013.090282

DO - 10.3324/haematol.2013.090282

M3 - Article

C2 - 23812943

AN - SCOPUS:84886997780

VL - 98

SP - 1686

EP - 1688

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 11

ER -